The off-label use of prescription drugs in the United States is extremely common. Studies reveal that as much as 1 in 5 prescriptions are not used for their approved use by the Food & drug Administration. A new study reports that physician’s who prescribe drugs for off-label use are being paid to promote the drug.
What Is The Off-Label Use Of Prescription Drugs?
Off-label marketing is the promotion by a manufacturer of a drug for use in a condition or age group, or in a dose or form of administration that has not been specifically approved by a drugs regulatory body; it is illegal in the United States. Yet, some still do it, and then pay a physician to prescribe it off-label, or pay them to promote the drug within their published studies. But, as stated this is illegal, as well as a conflict-of-interest.
Physicians Not Forthcoming With Big Pharma Relationships
And according to a study by international researchers, conflict-of-interest statements made by physicians and scientists in their medical journal articles after they had been allegedly paid by pharmaceutical manufacturers as part of off-label marketing programs are often inadequate, highlighting the deficiencies in relying on author candidness and the weaknesses in some journal practices in ensuring proper disclosure, according to the study published in PLoS Medicine.
So in other words, when the physician is caught with their hand in the cookie jar, so to speak, the majority of them are not coming completely clean with their actions.
In an analysis led by Aaron Kesselheim from Brigham and Women’s Hospital in Boston, the authors from the US and Australia found that overall, only one in seven authors reported by whistleblowers to be involved in off-label marketing activities fully disclosed their conflict of interest in published articles.
The authors reached these conclusions by examining 26 whistleblower complaints of illegal off-label promotion and identified the 91 doctors and scientists recorded as being involved in this practice. The researchers found 39 (43%) of these 91 experts had authored 404 publications related to the drugs at issue in the complaints. However, only 62 (15%) of these articles had adequate disclosures. Among the articles without adequate disclosures, 43% (148) had no disclosure at all, 4% had statements denying any conflicts of interest, 40% had disclosures that did not mention the drug manufacturer, and 13% had disclosures that mentioned the manufacturer but inadequately conveyed the nature of the relationship between author and drug manufacturer reported in the complaint.
The authors argue that such failures in relation to off-label marketing schemes are especially troubling because off-label use is an area of clinical practice in which opinion is likely to be divided about appropriate care and there is no guidance from regulatory authorities. Therefore, high-profile ”opinion leaders” may exert considerable influence on prescribing practices through their publications. The authors argue: “More adequate disclosure of financial ties in these situations would give readers an opportunity to weigh the potential for bias.”
The authors conclude: “Our findings suggest that approaches to controlling the effects of conflicts of interest that rely on author candidness and variable policing by journals have fallen short of the mark. Readers are left with little choice but to be skeptical.”
You May Like[related_posts limit=”5″]